Followers | 134 |
Posts | 7040 |
Boards Moderated | 0 |
Alias Born | 02/09/2012 |
Saturday, November 06, 2021 12:49:00 PM
IMO...Dr. Zasloff's quote in 1988...indicates that developing his peptide disease (bacterial and viral infections) by testing of peptide attributes and mechanisms HAS COME TO FRUITION 33 YEARS LATER...via TEAM DEGRADO'S DEVELOPMENT AND CLINICAL TRIALS BRILAICIDN for COVID-19 and Variants.
As CITED BY LEO in a previous PR... Dr. Zasloff acknowledged the validity of the bacterial and viral destructive mechanisms of Brilacidin (a DeNovo Peptide developed by Dr. DeGrado/Team) in stating:
...
The ABSSSI Clinical Trials demonstrated the efficacy of Brilacidin vs. bacteria cells (destroying the cells via creating an immediate electrical imbalance in the outer-cell). and IMO the CURRENT CLINICAL TRAILS are about to demonstrate the same for enveloped VIRAL CELLS (which is the structure of Covid-19 and the vast majority of Viruses)
Dr. Zasloff noted in 1988...
It would appear that "Dr. DeGrado/Team's" development of Brilacidin was inspired and spurred on by and Dr. Zasloff's frog peptide (magainin molecules) discovery.
A very similar description of the Destructive Mechanisms of Brilacidin to the Cell Structure of enveloped Bacteria and Virus cells...by DeGrado/TEAM...i.e. destabilizing the outer shell of the cells...much like a "pin popping a balloon" ... was made by Dr. Zasloff regarding the peptide (magainin) action he discovered:
...in the end, Brilacidin has two huge SCIENTIFIC ENDORSERS of its Mechanism for immediately destroying both Bacteria and Virus enveloped cells (almost all )...Dr. Zasloff and Dr. DeGrado ...one in the Discovery of Peptides and destruction of Bacteria/Viruses (and beyond) in the animal kingdom, and the later in the DEVELOPMENT OF DE NOVO peptide sequencing and the end product...BRILACIDIN
Know what you own!
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM